Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Mirum Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MIRM
Nasdaq
8731
https://mirumpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
- Apr 25th, 2024 2:02 pm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 11th, 2024 1:30 am
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
- Apr 2nd, 2024 12:30 pm
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
- Mar 29th, 2024 3:30 pm
Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares
- Mar 26th, 2024 3:46 am
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
- Mar 25th, 2024 11:00 am
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
- Mar 15th, 2024 1:32 pm
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
- Mar 13th, 2024 10:00 pm
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
- Mar 5th, 2024 1:00 pm
Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat
- Feb 29th, 2024 4:34 pm
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript
- Feb 29th, 2024 2:49 pm
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
- Feb 29th, 2024 1:30 pm
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
- Feb 28th, 2024 10:35 pm
Mirum Pharmaceuticals Inc (MIRM) Reports Robust Revenue Growth and Expanding Commercial ...
- Feb 28th, 2024 9:38 pm
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
- Feb 28th, 2024 9:03 pm
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
- Feb 21st, 2024 9:05 pm
Sarepta Therapeutics (SRPT) Moves 7.8% Higher: Will This Strength Last?
- Feb 19th, 2024 8:26 am
Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback
- Jan 23rd, 2024 4:44 pm
Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
- Jan 16th, 2024 1:30 pm
Should You Invest in Mirum Pharmaceuticals (MIRM)?
- Jan 15th, 2024 9:03 am
Scroll